EquitySector - HealthcareVery High Risk
Regular
NAV (03-Jul-25)
Returns (Since Inception)
Fund Size
₹332 Cr
Expense Ratio
2.38%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+27.15%
+17.72% (Cat Avg.)
Since Inception
+24.57%
— (Cat Avg.)
Equity | ₹311.32 Cr | 93.87% |
Others | ₹20.35 Cr | 6.13% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹29.04 Cr | 8.76% |
Divi's Laboratories Ltd | Equity | ₹25.75 Cr | 7.76% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹24.95 Cr | 7.52% |
Cipla Ltd | Equity | ₹18.79 Cr | 5.66% |
Fortis Healthcare Ltd | Equity | ₹16.99 Cr | 5.12% |
Lupin Ltd | Equity | ₹15.7 Cr | 4.73% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹12.89 Cr | 3.89% |
Torrent Pharmaceuticals Ltd | Equity | ₹12.29 Cr | 3.71% |
Laurus Labs Ltd | Equity | ₹11.71 Cr | 3.53% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹11.04 Cr | 3.33% |
Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹9.11 Cr | 2.75% |
Emcure Pharmaceuticals Ltd | Equity | ₹8.79 Cr | 2.65% |
Apollo Hospitals Enterprise Ltd | Equity | ₹8.68 Cr | 2.62% |
Ipca Laboratories Ltd | Equity | ₹8.35 Cr | 2.52% |
Abbott India Ltd | Equity | ₹7.45 Cr | 2.25% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.71 Cr | 2.02% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹6.67 Cr | 2.01% |
Kovai Medical Center & Hospital Ltd | Equity | ₹6.59 Cr | 1.99% |
Ajanta Pharma Ltd | Equity | ₹5.64 Cr | 1.70% |
Shaily Engineering Plastics Ltd | Equity | ₹5.56 Cr | 1.68% |
Jupiter Life Line Hospitals Ltd | Equity | ₹5.25 Cr | 1.58% |
Neuland Laboratories Ltd | Equity | ₹5.2 Cr | 1.57% |
Pfizer Ltd | Equity | ₹5.17 Cr | 1.56% |
Thyrocare Technologies Ltd | Equity | ₹5.14 Cr | 1.55% |
Strides Pharma Science Ltd | Equity | ₹4.62 Cr | 1.39% |
Acutaas Chemicals Ltd | Equity | ₹4.46 Cr | 1.35% |
Alembic Pharmaceuticals Ltd | Equity | ₹4.29 Cr | 1.29% |
FDC Ltd | Equity | ₹4.09 Cr | 1.23% |
India (Republic of) | Bond - Short-term Government Bills | ₹3.98 Cr | 1.20% |
Global Health Ltd | Equity | ₹3.97 Cr | 1.20% |
RPG Life Sciences Ltd | Equity | ₹3.61 Cr | 1.09% |
India (Republic of) | Bond - Short-term Government Bills | ₹3.07 Cr | 0.93% |
Supriya Lifescience Ltd | Equity | ₹2.98 Cr | 0.90% |
Net Receivables / (Payables) | Cash - Collateral | ₹2.5 Cr | 0.75% |
PB Fintech Ltd | Equity | ₹2.31 Cr | 0.70% |
Laxmi Dental Ltd | Equity | ₹2.24 Cr | 0.68% |
Navin Fluorine International Ltd | Equity | ₹2.12 Cr | 0.64% |
Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.99 Cr | 0.60% |
Poly Medicure Ltd | Equity | ₹1.9 Cr | 0.57% |
Blue Jet Healthcare Ltd | Equity | ₹1.87 Cr | 0.56% |
Jubilant Ingrevia Ltd Ordinary Shares | Equity | ₹1.82 Cr | 0.55% |
Rainbow Childrens Medicare Ltd | Equity | ₹1.56 Cr | 0.47% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹1.49 Cr | 0.45% |
Vijaya Diagnostic Centre Ltd | Equity | ₹1.39 Cr | 0.42% |
91 Days Tbill Red 19-06-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.15% |
91 Days Treasury Bill 26-Jun-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.15% |
364 DTB 28082025 | Bond - Gov't/Treasury | ₹0.49 Cr | 0.15% |
Dr Reddy's Laboratories Ltd | Equity | ₹0.25 Cr | 0.08% |
182 DTB 05062025 | Bond - Gov't/Treasury | ₹0.2 Cr | 0.06% |
Large Cap Stocks
25.96%
Mid Cap Stocks
29.18%
Small Cap Stocks
38.04%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹295.04 Cr | 88.96% |
Basic Materials | ₹13.96 Cr | 4.21% |
Financial Services | ₹2.31 Cr | 0.70% |
Standard Deviation
This fund
--
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
1.14
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
2.10
Higher the better
Since February 2024
Since February 2024
Since May 2025
Since February 2024
Since January 2025
ISIN INF03VN01878 | Expense Ratio 2.38% | Exit Load 1.00% | Fund Size ₹332 Cr | Age 1 year 4 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (03-Jul-25)
Returns (Since Inception)
Fund Size
₹332 Cr
Expense Ratio
2.38%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+27.15%
+17.72% (Cat Avg.)
Since Inception
+24.57%
— (Cat Avg.)
Equity | ₹311.32 Cr | 93.87% |
Others | ₹20.35 Cr | 6.13% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹29.04 Cr | 8.76% |
Divi's Laboratories Ltd | Equity | ₹25.75 Cr | 7.76% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹24.95 Cr | 7.52% |
Cipla Ltd | Equity | ₹18.79 Cr | 5.66% |
Fortis Healthcare Ltd | Equity | ₹16.99 Cr | 5.12% |
Lupin Ltd | Equity | ₹15.7 Cr | 4.73% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹12.89 Cr | 3.89% |
Torrent Pharmaceuticals Ltd | Equity | ₹12.29 Cr | 3.71% |
Laurus Labs Ltd | Equity | ₹11.71 Cr | 3.53% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹11.04 Cr | 3.33% |
Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹9.11 Cr | 2.75% |
Emcure Pharmaceuticals Ltd | Equity | ₹8.79 Cr | 2.65% |
Apollo Hospitals Enterprise Ltd | Equity | ₹8.68 Cr | 2.62% |
Ipca Laboratories Ltd | Equity | ₹8.35 Cr | 2.52% |
Abbott India Ltd | Equity | ₹7.45 Cr | 2.25% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.71 Cr | 2.02% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹6.67 Cr | 2.01% |
Kovai Medical Center & Hospital Ltd | Equity | ₹6.59 Cr | 1.99% |
Ajanta Pharma Ltd | Equity | ₹5.64 Cr | 1.70% |
Shaily Engineering Plastics Ltd | Equity | ₹5.56 Cr | 1.68% |
Jupiter Life Line Hospitals Ltd | Equity | ₹5.25 Cr | 1.58% |
Neuland Laboratories Ltd | Equity | ₹5.2 Cr | 1.57% |
Pfizer Ltd | Equity | ₹5.17 Cr | 1.56% |
Thyrocare Technologies Ltd | Equity | ₹5.14 Cr | 1.55% |
Strides Pharma Science Ltd | Equity | ₹4.62 Cr | 1.39% |
Acutaas Chemicals Ltd | Equity | ₹4.46 Cr | 1.35% |
Alembic Pharmaceuticals Ltd | Equity | ₹4.29 Cr | 1.29% |
FDC Ltd | Equity | ₹4.09 Cr | 1.23% |
India (Republic of) | Bond - Short-term Government Bills | ₹3.98 Cr | 1.20% |
Global Health Ltd | Equity | ₹3.97 Cr | 1.20% |
RPG Life Sciences Ltd | Equity | ₹3.61 Cr | 1.09% |
India (Republic of) | Bond - Short-term Government Bills | ₹3.07 Cr | 0.93% |
Supriya Lifescience Ltd | Equity | ₹2.98 Cr | 0.90% |
Net Receivables / (Payables) | Cash - Collateral | ₹2.5 Cr | 0.75% |
PB Fintech Ltd | Equity | ₹2.31 Cr | 0.70% |
Laxmi Dental Ltd | Equity | ₹2.24 Cr | 0.68% |
Navin Fluorine International Ltd | Equity | ₹2.12 Cr | 0.64% |
Dr Agarwal'S Eye Hospital Ltd | Equity | ₹1.99 Cr | 0.60% |
Poly Medicure Ltd | Equity | ₹1.9 Cr | 0.57% |
Blue Jet Healthcare Ltd | Equity | ₹1.87 Cr | 0.56% |
Jubilant Ingrevia Ltd Ordinary Shares | Equity | ₹1.82 Cr | 0.55% |
Rainbow Childrens Medicare Ltd | Equity | ₹1.56 Cr | 0.47% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹1.49 Cr | 0.45% |
Vijaya Diagnostic Centre Ltd | Equity | ₹1.39 Cr | 0.42% |
91 Days Tbill Red 19-06-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.15% |
91 Days Treasury Bill 26-Jun-2025 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.15% |
364 DTB 28082025 | Bond - Gov't/Treasury | ₹0.49 Cr | 0.15% |
Dr Reddy's Laboratories Ltd | Equity | ₹0.25 Cr | 0.08% |
182 DTB 05062025 | Bond - Gov't/Treasury | ₹0.2 Cr | 0.06% |
Large Cap Stocks
25.96%
Mid Cap Stocks
29.18%
Small Cap Stocks
38.04%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹295.04 Cr | 88.96% |
Basic Materials | ₹13.96 Cr | 4.21% |
Financial Services | ₹2.31 Cr | 0.70% |
Standard Deviation
This fund
--
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
1.14
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
2.10
Higher the better
Since February 2024
Since February 2024
Since May 2025
Since February 2024
Since January 2025
ISIN INF03VN01878 | Expense Ratio 2.38% | Exit Load 1.00% | Fund Size ₹332 Cr | Age 1 year 4 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments